Beam Therapeutics up after FDA's tag for sickle cell therapy

Beam Therapeutics

14/08/2025 12:23

** Shares of Beam Therapeutics BEAM.O up 2.11% at $17.89 premarket

** Biotech firm says U.S. FDA has granted regenerative medicine advanced therapy (RMAT) designation to its experimental cell therapy, BEAM-101, for the treatment of sickle cell disease

** The RMAT tag is designed to support the development and evaluation of regenerative medicines, including genetic therapies, with the intention of addressing serious or life-threatening diseases that have unmet medical needs

** Sickle cell disease is a severe inherited blood disease that affects the shape of red blood cells, which carry oxygen to all parts of the body

** Up to last close, shares down 29% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))